Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
Lishi Lin, Egbert F. Smit, Adrianus J. de Langen, Dorieke E.M. van Balen, Jos H. Beijnen, Alwin D.R. Huitema
Research output: Contribution to journal › Article › peer-review
3Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice'. Together they form a unique fingerprint.